What Happened
Verdiva Bio has terminated a Phase 2 trial testing whether its once-weekly oral GLP-1 candidate, VRB-101, could maintain weight loss in people who had already reduced their weight on injectable GLP-1 therapy. The public trial registry entry states plainly that the sponsor made a business decision to stop the study and that the decision was not based on safety findings.
The terminated study (NCT07553299) had enrolled just 8 participants against a planned total of roughly 120. It was designed to identify the optimal weekly oral dose of VRB-101 — an oral formulation of the GLP-1 analog ecnoglutide — for keeping weight off in people with obesity who had achieved at least 10% weight reduction during six months of prior treatment with injectable semaglutide or tirzepatide.
A company spokesperson described the move as a refinement of the clinical development plan for VRB-101 "in light of market evolution" — signaling a strategic refocus rather than a setback with the molecule itself.
Who Is Affected
- Trial participants: The small number of enrolled participants completed their safety follow-up.
- Obesity researchers: Weight maintenance after injectable GLP-1 therapy has become one of the most competitive frontiers in metabolic medicine, and a clinical-stage biotech stepping back from that channel says a great deal about the commercial landscape.
- Pipeline watchers: Verdiva launched in early 2025 with $411 million in financing to advance weight-loss candidates in-licensed from Sciwind Biosciences, and the maintenance indication was one of several planned uses for VRB-101.
Importantly, the termination does not affect the broader VRB-101 program. The 206-participant Phase 2b EVOLVE-2 weight-reduction study completed in July, with topline data expected by the end of 2026, and a Phase 1 combination trial pairing oral VRB-101 with the oral amylin analog VRB-103 is ongoing.
Timeline
- Early 2025: Verdiva Bio launches with $411 million in Series A financing, licensing VRB-101 and a portfolio of amylin-based candidates from Sciwind Biosciences.
- June 2026: The Phase 2 weight-maintenance study begins enrolling.
- July 2026: The Phase 2b EVOLVE-2 weight-reduction study completes with 206 participants; a Phase 1 combination study of oral VRB-103 alone and alongside VRB-101 starts.
- September 2026: The maintenance study is formally ended, with only 8 participants ever enrolled.
- October 2026: The termination and its business rationale appear in the public trial registry, confirming the program refocus.
What This Means for Researchers
The "market evolution" behind the decision is clear. Large pharmaceutical companies are moving into both oral GLP-1 medicines and dedicated weight-maintenance indications. Recent Phase 3b data showed that switching from injectable GLP-1 therapy to an oral agent can preserve most prior weight loss, and lower-dose maintenance formulations of approved injectables are advancing through late-stage testing. For a clinical-stage biotech, that specific channel may no longer have offered a differentiated path.
For the research community, the episode is also a reminder that early-phase pipeline news is volatile. A candidate's clinical trajectory can shift for purely commercial reasons, with no implication about its safety profile or pharmacology. Verdiva's own monotherapy and combination programs for VRB-101 continue unchanged.
How to Verify Your Peptides
Unapproved GLP-1 analogs circulate widely in the gray market, and pipeline news often triggers renewed interest in research compounds. Independent analytical verification is essential:
- See how lab testing works
- Understand HPLC vs LC-MS verification
- Check identity, purity, and fill weight basics
- Review common testing questions
Safe Alternatives
- Browse compound profiles in our peptides reference section
- Compare sources on our vetted vendor directory
Sources
Regulatory announcements; public clinical trial registry documentation; industry reports.